Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

479 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.
Cabezón M, Bargay J, Xicoy B, García O, Borrás J, Tormo M, Marcé S, Pedro C, Valcárcel D, Jiménez MJ, Guàrdia R, Palomo L, Brunet S, Vall-Llovera F, Garcia A, Feliu E, Zamora L; CETLAM Group. Cabezón M, et al. Among authors: borras j. Oncotarget. 2018 Apr 10;9(27):19342-19355. doi: 10.18632/oncotarget.25046. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721207 Free PMC article.
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Cabezón M, Malinverni R, Bargay J, Xicoy B, Marcé S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jiménez MJ, Hoyos M, Valcárcel D, Escoda L, Vall-Llovera F, Garcia A, Font LL, Rámila E, Buschbeck M, Zamora L; CETLAM group. Cabezón M, et al. Among authors: borras j. Clin Epigenetics. 2021 Jan 14;13(1):9. doi: 10.1186/s13148-021-01002-y. Clin Epigenetics. 2021. PMID: 33446256 Free PMC article.
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
Triguero A, Xicoy B, Zamora L, Jiménez MJ, García O, Calabuig M, Díaz-Beyá M, Arzuaga J, Ramos F, Medina A, Bernal T, Talarn C, Coll R, Collado R, Chen TH, Borrás J, Brunet S, Marchante I, Marco V, López-Cadenas F, Calbacho M, Simiele A, Cortés M, Cedena MT, Pedreño M, Aguilar C, Pedró C, Fernández M, Stoica C, Ribera JM, Sanz G. Triguero A, et al. Among authors: borras j. Leuk Res. 2022 May;116:106836. doi: 10.1016/j.leukres.2022.106836. Epub 2022 Mar 26. Leuk Res. 2022. PMID: 35405632
[The risk of breast cancer in Catalonia].
Izquierdo A, Viladiu P, Borrás J, Galcerán J, Borràs JM, Dorca J, Vayreda J, Moreno V. Izquierdo A, et al. Among authors: borras j, borras jm. Med Clin (Barc). 1996 Oct 5;107(11):410-3. Med Clin (Barc). 1996. PMID: 9045002 Spanish.
Cancer incidence and mortality projections up to 2020 in Catalonia by means of Bayesian models.
Ribes J, Esteban L, Clèries R, Galceran J, Marcos-Gragera R, Gispert R, Ameijide A, Vilardell ML, Borras J, Puigdefabregas A, Buxó M, Freitas A, Izquierdo A, Borras JM. Ribes J, et al. Among authors: borras j, borras jm. Clin Transl Oncol. 2014 Aug;16(8):714-24. doi: 10.1007/s12094-013-1140-z. Epub 2013 Dec 12. Clin Transl Oncol. 2014. PMID: 24338506
[The impact of cancer in Catalonia. Introduction].
Borràs JM, Borràs J, Gispert R, Izquierdo A. Borràs JM, et al. Among authors: borras j. Med Clin (Barc). 2008 Oct;131 Suppl 1:2-3. doi: 10.1016/s0025-7753(08)76426-1. Med Clin (Barc). 2008. PMID: 19080808 Spanish. No abstract available.
Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic?
Marcos-Gragera R, Vilar-Coromina N, Galceran J, Borràs J, Clèries R, Ribes J, Gispert R, Izquierdo A, Borràs JM. Marcos-Gragera R, et al. Among authors: borras j, borras jm. J Eur Acad Dermatol Venereol. 2010 Sep;24(9):1083-8. doi: 10.1111/j.1468-3083.2010.03602.x. Epub 2010 Mar 5. J Eur Acad Dermatol Venereol. 2010. PMID: 20236382
479 results